Evidence-Based Patient-Centered Management in NSCLC
Hematology-Oncology
Curriculum:
A Patient-Centric, Performance Measures-Based Approach to NSCLC
A Patient-Centric, Performance Measures-Based Approach to NSCLC
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
February 02, 2017
February 02, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Oncology specialists, including physicians, nurse practitioners, and physician assistants
Relevant Terms:
Non-small cell lung cancer
Daniel Morgensztern, MD
Daniel Morgensztern, MD
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri
Bio
Daniel Morgensztern, MD, is an associate professor at Washington University School of Medicine and Director of Thoracic Medical Oncology. He graduated from FTE Souza Marques in Brazil followed, by a residency in internal medicine and a fellowship in hematology-oncology at the University of Miami School of Medicine.
Among Dr. Morgensztern’s awards are the first place in the Doctor’s Dilemma Competition from the American College of Physicians in Florida, Young Investigator Award from the American Society of Clinical Oncology, American Society of Clinical Oncology Merit Award, David S Fischer Award for Outstanding Teaching and Mentoring Fellows in Medical Oncology at the Yale Cancer Center, and Teacher of the Year award for the Hematology-Oncology Fellowship Program at Washington University.
Thomas E. Stinchcombe, MD
Thomas E. Stinchcombe, MD
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina
Bio
Thomas E. Stinchcombe, MD, completed medical school at the University of Virginia, an internal medicine residency at the University of Michigan, and a hematology and oncology fellowship at the University of North Carolina.Dr. Stinchcombe’s clinical interest is in thoracic malignancies, and his research focus is clinical trials for non-small cell and small cell lung cancer. He is a member of the Duke Cancer Institute and the Thoracic Oncology Program at Duke University in Durham, North Carolina.
Jamie E. Chaft, MD
Jamie E. Chaft, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York
Bio
Jamie E. Chaft, MD, is assistant attending physician at Memorial Sloan Kettering Cancer Center and an assistant professor at Weill Cornell Medical College. She completed her internal medicine internship and residency at Weill Cornell Medical College in New York Presbyterian Hospital and completed her medical oncology fellowship at Memorial Sloan Kettering Cancer Center. She is a member of the Thoracic Oncology Service with a focus on clinical research and treatment of patients with thoracic malignancies.Serving as a principal investigator, Dr. Chaft has participated in and led many research studies. Her clinical research focus includes multimodality therapy for the treatment of early stage lung cancer and the use of immunotherapies as treatment of patients with lung cancers. Her studies aim to utilize drugs that show promise in metastatic lung cancers in patients with potentially curable disease. She has published on the use of bevacizumab and gefitinib in early stage lung cancers and is the study chair of the National Cancer Institute-sponsored study of adjuvant nivolumab after curative lung cancer resection.
| 1. | Utilize a comprehensive understanding of histopathologic and molecular underpinnings of non-small cell lung cancer (NSCLC) and efficacy and safety data for agents used to treat NSCLC to select the most appropriate personalized therapies | 2. | Implement the most effective treatment strategies for patients with advanced NSCLC using current evidence-based guidelines for sequencing, combination chemotherapy, and targeted therapy |
| 3. | Engage patients with advanced NSCLC in their healthcare by implementing effective shared decision-making strategies |
| 1. | Utilize a comprehensive understanding of histopathologic and molecular underpinnings of non-small cell lung cancer (NSCLC) and efficacy and safety data for agents used to treat NSCLC to select the most appropriate personalized therapies |
| 2. | Implement the most effective treatment strategies for patients with advanced NSCLC using current evidence-based guidelines for sequencing, combination chemotherapy, and targeted therapy |
| 3. | Engage patients with advanced NSCLC in their healthcare by implementing effective shared decision-making strategies |
PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Daniel Morgensztern, MD, has affiliations with Bristol-Myers Squibb (BMS) and Genentech (Consulting Fees).
- Jamie E. Chaft, MD, has affiliations with AstraZeneca and Genentech (Consulting Fees); and AstraZeneca, BMS, and Genentech (Research).
- Thomas E. Stinchcombe, MD, has affiliations with ARIAD, Boehringer Ingelheim, Celgene, and Helsinn (Consulting Fees).
RMEI Medical Education, LLC
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Joanne M. Faysal, MS, has no affiliations with commercial interests to disclose.
- Marie N. Becker, PhD has no affiliations with commercial interests to disclose.
- Nora Hartley has no affiliations with commercial interests to disclose.
- Amy Reeve has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1 hour
Medium: Internet
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by independent educational grants from Genentech and Lilly.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
